Lv1
10 积分 2022-08-08 加入
Once-weekly semaglutide 2·4 mg in an Asian population with obesity, defined as BMI ≥25 kg/m2, in South Korea and Thailand (STEP 11): a randomised, double-blind, placebo-controlled, phase 3 trial
2个月前
已完结
Efficacy and safety of a biased GLP-1 receptor agonist ecnoglutide in adults with overweight or obesity: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
2个月前
已完结
Semaglutide in obesity-related heart failure with preserved ejection fraction and type 2 diabetes across baseline HbA1c levels (STEP-HFpEF DM): a prespecified analysis of heart failure and metabolic outcomes from a randomised, placebo-controlled trial
2个月前
已完结
Efficacy and safety of semaglutide versus placebo for people with schizophrenia on clozapine with obesity (COaST): a phase 2, multi-centre, participant and investigator- blinded, randomised controlled trial in Australia
2个月前
已关闭
Efficacy and safety of once weekly semaglutide 2·4 mg for weight management in a predominantly east Asian population with overweight or obesity (STEP 7): a double-blind, multicentre, randomised controlled trial
2个月前
已完结
Population Pharmacokinetic Modeling of Cotadutide: A Dual Agonist Peptide of Glucagon-Like Peptide and Glucagon Receptors Administered to Participants with Type II Diabetes Mellitus, Chronic Kidney Disease, Obesity and Non-Alcoholic Steatohepatitis
2个月前
已完结
Budesonide in previously untreated autoimmune hepatitis
3个月前
已完结
[Autoimmune hepatitis. Clinical characteristics and response to treatment in a series of 49 spanish patients]
3个月前
已关闭
[Effect of long-term ursodeoxycholic acid treatment on serum liver enzymes and serum bile acid metabolism in chronic hepatitis]
3个月前
已关闭
Deflazacort for long-term maintenance of remission in type I autoimmune hepatitis
3个月前
已关闭
皖公网安备34019202002308
